Mike Carrel, CEO of Cincinnati-based AtriCure for about a year, will open what looks like a shadow headquarters and R&D facility for the atrial fibrillation products company in Minnetonka in March.
"The executive team will be split," Carrel said in an interview. "I told the board [when hired] that I wasn't moving to Cincinnati. It's also important to set up research and development in the Twin Cities where we'll partner with the University of Minnesota. We're hiring engineering, marketing, a vice president of business development. … There's a lot of talent in the Twin Cities. We're not moving the whole company here. Manufacturing is well-established there."
AtriCure (ticker: ATRC), has seen its stock price double to nearly $19 per share over the last year, a market value approaching $400 million. There's growing revenue from surgical to minimally invasive products that solve the problem of an irregular and often rapid heart rate that commonly causes poor blood flow to the body.
Carrel stayed on as the boss at Vital Images to handle the integration after he sold the medical imaging-software firm to Toshiba Medical Systems in a $273 million deal in 2011.
Carrel said he expects to employ up to 20 people in a leased facility in the Carlson East office park.
AtriCure was a medical start-up company that went public in 2005.
First light manager likes AtriCure, other small med-techs
AtriCure is one of the 10 biggest holdings in the portfolio of Matt Arens, CEO and senior portfolio manager at First Light Asset Management of Bloomington.
Arens, who spent 15 years at Kopp Investment Advisors before opening his own shop in September, has hit $120 million in assets with a portfolio guided by his longtime belief that "a disproportionate number of health care innovations tend to come from smaller, more agile companies with disruptive technologies."